⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EYPT News
EyePoint Pharmaceuticals, Inc. Common Stock
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT
Form 8-K
sec.gov
EYPT
Form 8-K
sec.gov
EYPT
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT
Form 8-K
sec.gov
EYPT
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
globenewswire.com
EYPT
Form 8-K
sec.gov
EYPT
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
globenewswire.com
EYPT
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
globenewswire.com
EYPT
EyePoint Announces Participation at Upcoming Investor Conferences
globenewswire.com
EYPT